Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760578 · ClinicalTrials.gov registry record · Phase 2
A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator
A Phase 2 study, sponsored by Metabolic Solutions Development Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00760578 is a Phase 2 study that has completed, run by Metabolic Solutions Development Company. The registered enrollment target is 86 participants.
The verdict
NCT00760578, a Phase 2 study, has completed, sponsored by Metabolic Solutions Development Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
Interventions
- DRUG Placebo
- DRUG Pioglitazone
- DRUG MSDC-0160 90 mg
- DRUG MSDC-0160 220 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760578
The ClinicalTrials.gov registry entry for NCT00760578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metabolic Solutions Development Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00760578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00760578 about?
NCT00760578 is a clinical study titled "A Placebo Controlled Safety and Efficacy Study of MSDC-0160 in Type 2 Diabetes With Active Comparator". The purpose of this study is to determine if MSDC-0160 is effective in the treatment of Type 2 diabetes.
What is the current status of trial NCT00760578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2008-09. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00760578?
The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG), MSDC-0160 90 mg (DRUG), MSDC-0160 220 mg (DRUG).
Who is sponsoring clinical trial NCT00760578?
This trial is sponsored by Metabolic Solutions Development Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.